NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NYSE · Diagnostics & Research · USD

IQVIA Holdings Inc. (IQV) Stock Analysis

IQVIA Holdings Inc. (IQV) is a Diagnostics & Research stock listed on NYSE and quoted in US Dollar.

Last Updated: October 21, 2026

IQV

$276.63

+$8.78 (+3.28%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare IQV with… →

IQV Key Statistics

As of Oct 21, 2026
Trading
Open
$264.46
Previous Close
$267.85
Day's Range
263.97–277.28
52-Week Range
154.50–277.40
Volume
1.75M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.17
Valuation
Market Cap
$45.53B
P/E Ratio
34.36
Forward P/EShare price divided by forecast earnings for the year ahead, rather than the year just past.
19.21
PEG RatioThe P/E ratio divided by the expected earnings growth rate. It puts a high P/E in the context of how fast profits are growing.
0.97
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
2.68
EPS (ttm)Profit attributable to each share over the last twelve months.
8.05
Financials (FY)
Revenue (FY)
$16.31B+5.87%
Net Income (FY)
$1.36B−0.95%
Profit marginThe share of revenue left as profit after all costs and taxes.
8.10%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
164.60M
1-Year Return
+26.51%
Dividend and dates
Earnings Date
October 27, 2026
Avg Volume
1.46M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, IQV closed at $276.63, +26.51% over 1 year.

IQVIA Holdings Inc. (IQV) has a market capitalization of $45.53B.

In fiscal 2025, IQV reported revenue of $16.31B.

IQV Stock Return by Calendar Year

IQVIA Holdings Inc. (IQV) 10-year return: what $10,000 became

1 year
$10,000 $12,651
+26.51%
5 years
$10,000 $10,855
+8.55%
10 years
$10,000 $37,372
+273.72%

If you had invested $10,000 in IQVIA Holdings Inc. (IQV) 10 years ago, at the close on October 21, 2016, it would have been worth $37,372 at the close on October 21, 2026: +273.72% in total, +14.09% a year. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+22.72%
2025+14.71%
2024−15.07%
2023+12.93%
2022−27.38%
2021+57.47%
2020+15.96%
2019+33.00%
2018+18.66%
2017+28.73%
2016 (partial year)−0.67%

As of October 21, 2026.

IQV Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$16.31B$1.36B8.3%
2024$15.41B$1.37B8.9%
2023$14.98B$1.36B9.1%
2022$14.41B$1.09B7.6%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$16.31B$5.43B$2.29B$1.36B8.3%
2024$15.41B$5.38B$2.27B$1.37B8.9%
2023$14.98B$5.24B$2.06B$1.36B9.1%
2022$14.41B$5.03B$1.83B$1.09B7.6%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

IQV Valuation vs Diagnostics & Research Median

Median of 45 stocks
MetricIQVDiagnostics & Research medianvs median
P/E34.3637.599% below
P/S ratio2.685.2349% below
Profit margin8.10%−0.93%9.0 pts above

Medians across 45 Diagnostics & Research stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

IQVIA Holdings Inc. (IQV) carries a market capitalisation of $45.53B. It is classified in the Diagnostics & Research industry, within the Healthcare sector. Headcount on file is 94,000.

IQV last closed at $276.63 on October 21, 2026. That is +$8.78 (+3.28%) against the previous close. The 52-week range on file runs from $154.50 to $277.40. The latest close sits 79.05% above that 52-week low.

Financial Health

In fiscal 2025, IQVIA Holdings Inc. reported revenue of $16.31B. That is +5.87% against the prior fiscal year, when revenue was $15.41B. The same year closed with net income of $1.36B. That is −0.95% against the prior fiscal year. Profit margin runs at 8.1%. That is 9 percentage points above the Diagnostics & Research median of −0.93%. Trailing earnings per share are 8.05.

Across the 4 fiscal years on file, revenue moves from $14.41B in 2022 to $16.31B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

IQV trades at a trailing price-to-earnings ratio of 34.36. That is 8.58% below the Diagnostics & Research median of 37.59. The forward P/E on file is 19.21. The PEG ratio, which sets the P/E against expected earnings growth, reads 0.97. The price-to-sales ratio is 2.68. On price-to-sales that is 48.71% below the Diagnostics & Research median of 5.23. 45 Diagnostics & Research companies report these metrics, and the medians quoted come from that group.

Over the trailing twelve months the total return is +26.51%. Across 10 years the annualized return works out at +14.09%. The reported beta is 1.17. Daily returns over the trailing 10 years annualize to a volatility of 32.38%.

Growth & Income

The record shows no dividend for IQV.

So far in 2026 the total return is +22.72%. The strongest complete calendar year on file is 2021 at +57.47%; the weakest is 2022 at −27.38%. Of the 9 complete calendar years on file, 7 finished higher.

Peer Comparison

IQVIA Holdings Inc. (IQV) operates in the Diagnostics & Research industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
IQVIA Holdings Inc. IQV $45.53B 34.4
Thermo Fisher Scientific Inc. TMO $256.61B 37.4
Danaher Corporation DHR $164.40B 41.7
Natera, Inc. NTRA $59.59B —

The Diagnostics & Research industry average P/E ratio is 37.6x. IQVIA Holdings Inc. trades at a P/E of 34.4.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Diagnostics & Research Stocks

TMO

Thermo Fisher Scientific Inc.

$256.61B

 DHR

Danaher Corporation

$164.40B

 NTRA

Natera, Inc.

$59.59B

 A

Agilent Technologies, Inc.

$50.12B

 WAT

Waters Corporation

$44.92B

 IDXX

IDEXX Laboratories, Inc.

$43.60B
View all Diagnostics & Research stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About IQVIA Holdings Inc.

IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions. The Technology & Analytics Solutions segment offers a range of cloud-based applications and associated implementation services; real world solutions that enable life sciences and provider customers to generate and disseminate evidence, which informs health care decision making and improves patients' outcomes; and strategic and implementation consulting services, such as advanced analytics and commercial processes outsourcing services. This segment also provides country level performance metrics related to sales of pharmaceutical products, prescribing trends, medical treatment, and promotional activity across various channels, including retail, hospital, and mail order; and measurement of sales or prescribing activity at the regional, zip code, and individual prescriber level. The Research & Development Solutions segment offers project management and clinical monitoring; clinical trial support; strategic planning and design services; and patient and site centric solutions, as well as central laboratory, genomic, bioanalytical, ADME, discovery, vaccine and biomarker laboratory services. The Contract Sales & Medical Solutions segment provides health care provider and patient engagement services, and scientific strategy and medical services. It serves pharmaceutical, biotechnology, device and diagnostic, and consumer health companies. The company has a strategic collaboration with Kexing Biopharm Co., Ltd. for biosimilar development. The company was formerly known as Quintiles IMS Holdings, Inc. and changed its name to IQVIA Holdings Inc. in November 2017. IQVIA Holdings Inc. is based in Durham, North Carolina.

Visit website →